Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ACTRIMS 2024 | Highlights from ACTRIMS 2024

Barry Singer • 6 Mar 2024

ACTRIMS 2024

Multiple Sclerosis and Related Disorders

Barry Singer, MD, The MS Center for Innovations in Care, St. Louis, MO, shares key insights from the annual ACTRIMS Forum 2024 in the multiple sclerosis (MS) space. He highlights the scalable precision medicine open knowledge engine (SPOKE) database, employing artificial intelligence to predict MS development three years before onset with 83% accuracy. Additionally, Dr Singer discusses innovative research screening compounds for remyelination therapy, including a unique method utilizing 3D-printed artificial axons to evaluate agent efficacy. This interview took place during the annual ACTRIMS Forum 2024.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

An update on research in BTK inhibitors for the treatment of MS

Barry Singer • 6 Mar 2024

Transitioning from IV anti-CD20 therapy to ublituximab in MS: insights from ENHANCE

Barry Singer • 6 Mar 2024

FDA-approved anti-CD20 therapies for the treatment of MS: similarities and differences

Barry Singer • 6 Mar 2024

Improving comprehensive MS care through innovative and specialized approaches

Barry Singer • 28 Feb 2023

Related Videos

Navigating intra-individual variability for early detection of cognitive decline

Leigh Charvet • 23 Feb 2024

Acupressure for the management of pain and anxiety in patients with MS

Megan Weigel • 4 Mar 2024

Mapping the functional interactome in MS lesions to shed light on remyelination failure

Milos Opacic • 5 Mar 2024

GAIT-HUB: a home-based gait monitoring system for patients with MS

Giuseppina Pilloni • 4 Mar 2024